Search Results - predicted+novelty

105 Results

Sort By:

Novel Therapeutic Drug for Multiple Sclerosis

INVENTION NOVELTY This molecule, through its action on a unique target that is different from current therapeutic treatments for MS, has both immunosuppressive and neuromodulatory properties that will better prevent the progression of MS and repair the neuronal damage caused by the immune cells in MS. Currently, there are no MS drugs in the market...

Published: 5/2/2024 | Inventor(s): Paul Kim, Michael Kornberg, Peter Calabresi, Solomon Snyder

Keywords(s): Chronic Inflammatory Diseases, CNS and Neurological Disorders, Disease Indication, Multiple Sclerosis, Multiple Sclerosis (MS), Neurodegeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Selective Targeting of a Novel Protective Anti-inflammatory Receptor in Human Mitochondria and its Role in Preserving Mitochondrial Functions

Unmet NeedAccording to WHO, over one billion people worldwide are living with elevated blood pressure which may lead to a range of adverse health conditions that cause ~1,100 deaths per day. Many current high blood pressure therapies focus on angiotensin receptor blocking drugs. Unfortunately, adverse events (e.g., renal dysfunction, hyperkalemia, and...

Published: 5/2/2024 | Inventor(s): Andrew Cheetham, Peter Abadir, Jeremy Walston, Honggang Cui

Keywords(s): Antagonists/Inhibitors, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

In vivo and in vitro Role of Lactosylceramide Synthase (LCS) in Angiogenesis and LCS (B1, 4GalT-V) as a Bio-marker for Human Colon Cancer

Description: C10539: Use of Biomarker for Colon Cancer Diagnosis Value Proposition: ADVANTAGES • Colon cancer biomarker is directly included in panels of biomarkers for use in needle biopsies of colon tissue for early detection and diagnosis. • Colon cancer is the second largest mortality after cardiovascular disease. 90% of colorectal cancers...

Published: 5/2/2024 | Inventor(s): Subroto Chatterjee

Keywords(s): Antagonists/Inhibitors, Biomarker, Cancers, Clinical Diagnostics, Colorectal Cancer, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Colorectal Cancer

Biopolymer Encapsulation Increases the Bioavailability and Efficacy of D-PDMP in Interfering with Atherosclerosis and Cardiac Hypertrophy in apoE-/- Transgenic Mice

INVENTION NOVELTYA novel glycolipid inhibitor anti-atherosclerosis drug compound able to enhancegastro-intestinal absorption and residence time to reduce and ameliorateeffects of arteriosclerosis VALUE PROPOSITIONDespite great success of statins (cholesterol reducing agents), little is known aboutother molecules such as glycolipids that also rise with...

Published: 5/2/2024 | Inventor(s): Subroto Chatterjee

Keywords(s): Antagonists/Inhibitors, Cardiovascular Diseases, Disease Indication, Drug Delivery Vehicle, Non-novel, Off-the-shelf, Polymers, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

Hexosamine Analogs for Regenerative Medicine and Diseases Associated with the Musculoskeletal System

Unmet Need:Osteoarthritis (OA) is the most common form of arthritis, affecting an estimated 32.5 million adults in the United States, with an increasing incidence as the population ages (see CDC) . OA is associated with considerable morbidity as a consequence of joint damage, resulting in pain, loss of joint range of motion, and disability. The disease...

Published: 5/2/2024 | Inventor(s): Kevin Yarema, Jennifer Elisseeff, Jeannine Coburn, Udayanath Aich

Keywords(s): Antagonists/Inhibitors, Arthritis, Biologics, Carbohydrates, Disease Indication, Drug Delivery Mechanism, Drug Delivery Vehicle, Joint Disorders, Novel, Osteoarthritis, Predicted Novelty, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Rheumatology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Rheumatology > Arthritis, Clinical and Disease Specializations > Rheumatology > Osteoarthritis

O‐substituted hydroxamic acids with pyrazolone leaving groups as novel physiologically useful HNO donors

#C14009Inventor(s): John Toscano, Saghar Nourian, Daryl Guthrie Unmet NeedAn estimated 17.9 million people died from cardiovascular diseases in 2019, representing 32% of all global deaths (see WHO). Nitroglycerin has been used as a vasodilator to treat heart conditions for over 130 years. It wasn't until 2003 that scientists realized the beneficial...

Published: 5/2/2024 | Inventor(s): John Toscano, Saghar Nourian, Daryl Guthrie

Keywords(s): Cardiovascular Diseases, Congestive Heart Failure, Congestive Heart Failure (CHF), Disease Indication, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Cardiovascular > Congestive Heart Failure

Farnesylation of PARIS Prevents Dopaminergic Neurodegeneration in Models of Parkinson’s Disease

Unmet Need: Parkinson's disease (PD) is an incurable progressive neurodegenerative disease. It is characterized clinically by motor dysfunction that is due to the preferential loss of dopaminergic neurons in the brain. Current treatment strategies for PD are mainly limited to the management of the motor symptoms with drugs such as L-DOPA or dopamine...

Published: 5/2/2024 | Inventor(s): Ted Dawson, Valina Dawson, Joo-Ho Shin, Yunjong Lee, Areum Jo

Keywords(s): Agonists/Promoters, CNS and Neurological Disorders, Disease Indication, Non-novel, Off-the-shelf, Parkinson's Disease, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Parkinson's Disease

Design, Synthesis and Structure-activity Relationships of Pyridoquinazolinecarboxamides as RNA Polymerase I Inhibitors

This invention describes a set of novel small molecules that inhibit RNA polymerase I. RNA polymerase I (Pol I) governs the transcription of ribosomal RNAs, which are needed for building and function of the ribosomes. These ribosynthetic activities are greatly increased in cancer cells, and Pol I transcription rate is commonly deregulated in human cancers....

Published: 5/2/2024 | Inventor(s): Marikki Laiho, Sara Sanders, Laureen Colis, James Barrow, Glen Ernst

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Tonabersat as a Neuroprotective Compound for Amyotrophic Lateral Sclerosis

Unmet NeedAmytrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons, and results in muscle atrophy and loss of motor control. ALS affects approximately 17,000 people in the United States and 450,000 worldwide at any given time, and the average life expectancy from diagnosis to mortality is between 2-5 years....

Published: 5/2/2024 | Inventor(s): Nicholas Maragakis

Keywords(s): Amyotrophic Lateral Sclerosis, Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis

M4N and Temozolomide Combination Therapy for Glioblastoma multiforme (GBM)

Unmet NeedGlioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults and remains one of the most aggressive types of malignancies. The mainstay of GBM treatment is surgery, radiation and adjuvant chemotherapy using temozolomide (TMZ). While treatment options have incrementally improved, survival rates remains dismal. Only...

Published: 5/3/2024 | Inventor(s): Ru Chih Huang, Jong ho Chun, Yu-Ling Lin, Yu-Chuan Liang, Kuang-Wen Liao, Tiffany Jackson, David Mold, Chien-Hsien Lai

Keywords(s): Agonists/Promoters, Brain Cancer, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Glioblastoma, Glioma, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Brain Cancer

1 2 3 4 5 6 7 8 9 10 ...